214 related articles for article (PubMed ID: 22726592)
1. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group.
Kawaguchi S; Tsukahara T; Ida K; Kimura S; Murase M; Kano M; Emori M; Nagoya S; Kaya M; Torigoe T; Ueda E; Takahashi A; Ishii T; Tatezaki S; Toguchida J; Tsuchiya H; Osanai T; Sugita T; Sugiura H; Ieguchi M; Ihara K; Hamada K; Kakizaki H; Morii T; Yasuda T; Tanizawa T; Ogose A; Yabe H; Yamashita T; Sato N; Wada T
Cancer Sci; 2012 Sep; 103(9):1625-30. PubMed ID: 22726592
[TBL] [Abstract][Full Text] [Related]
2. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute.
Ida K; Kawaguchi S; Sato Y; Tsukahara T; Nabeta Y; Sahara H; Ikeda H; Torigoe T; Ichimiya S; Kamiguchi K; Wada T; Nagoya S; Hiraga H; Kawai A; Ishii T; Araki N; Myoui A; Matsumoto S; Ozaki T; Yoshikawa H; Yamashita T; Sato N
J Immunol; 2004 Jul; 173(2):1436-43. PubMed ID: 15240740
[TBL] [Abstract][Full Text] [Related]
3. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma.
Sato Y; Nabeta Y; Tsukahara T; Hirohashi Y; Syunsui R; Maeda A; Sahara H; Ikeda H; Torigoe T; Ichimiya S; Wada T; Yamashita T; Hiraga H; Kawai A; Ishii T; Araki N; Myoui A; Matsumoto S; Umeda T; Ishii S; Kawaguchi S; Sato N
J Immunol; 2002 Aug; 169(3):1611-8. PubMed ID: 12133991
[TBL] [Abstract][Full Text] [Related]
4. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma.
Kawaguchi S; Wada T; Ida K; Sato Y; Nagoya S; Tsukahara T; Kimura S; Sahara H; Ikeda H; Shimozawa K; Asanuma H; Torigoe T; Hiraga H; Ishii T; Tatezaki SI; Sato N; Yamashita T
J Transl Med; 2005 Jan; 3(1):1. PubMed ID: 15647119
[TBL] [Abstract][Full Text] [Related]
5. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.
Bloom JE; McNeel DG; Olson BM
Expert Rev Vaccines; 2012 Dec; 11(12):1401-4. PubMed ID: 23252384
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
12. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
13. [Roles of immunohistochemistry and detection of SYT-SSX fusion gene in diagnosis of synovial sarcoma].
Sun Y; Sun BC; Zhao XL; Wang J; Chen J; Li XQ; Feng YM; Fang ZW; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):480-4. PubMed ID: 17845763
[TBL] [Abstract][Full Text] [Related]
14. [Detection of SYT-SSX fusion gene in paraffin-embedded tissues and its clinicopathologic significance for synovial sarcoma].
Wei Y; Sun M; Zhu H; Xu Z; Wang J; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):426-30. PubMed ID: 11866984
[TBL] [Abstract][Full Text] [Related]
15. Detection of SYT-SSX fusion transcripts in paraffin-embedded tissues of synovial sarcoma by reverse transcription-polymerase chain reaction.
Wei Y; Wang J; Zhu X; Shi D; Hisaoka M; Hashimoto H
Chin Med J (Engl); 2002 Jul; 115(7):1043-7. PubMed ID: 12150740
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
17. SYT-SSX fusion proteins in synovial sarcomas: detection and characterization with new antibodies.
Hashimoto N; Araki N; Yoshikawa H; Myoui A; Matsumine A; Kaneko M; Sonobe H; Ochi T
Cancer Lett; 2000 Feb; 149(1-2):31-6. PubMed ID: 10737705
[TBL] [Abstract][Full Text] [Related]
18. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
19. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.
Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JS; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Cancer Res; 2002 Jan; 62(1):135-40. PubMed ID: 11782370
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
